Literature DB >> 1967523

Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection.

R E Anderson1, W Lang, S Shiboski, R Royce, N Jewell, W Winkelstein.   

Abstract

Serum beta 2-microglobulin (beta 2M) levels were measured by radioimmunoassay in 962 unmarried men recruited by probability sampling from areas in San Francisco, Calif, most severely affected by the epidemic of acquired immunodeficiency syndrome (AIDS). From July 1984 to December 1987, 65 incident AIDS cases occurred in 388 homosexual/bisexual men infected by the human immunodeficiency virus (HIV) at the time of recruitment. The mean level of beta 2M in uninfected individuals at entry was 170 nmol/L. In HIV-seropositive patients who had not developed AIDS, the mean beta 2M level was 254 nmol/L, and in those who had developed AIDS, the beta 2M level was 347 nmol/L. After 36 months of follow-up, 34% of individuals with beta 2M levels greater than 322 nmol/L at entry developed AIDS, 21% of individuals with levels between 246 and 322 nmol/L developed AIDS, while only 7.3% of those with levels below 246 nmol/L developed AIDS. The beta 2M level predicted the development of AIDS independently of the CD4 lymphocyte count in HIV-seropositive individuals. Thus, 65.5% of HIV-seropositive individuals with beta 2M levels above 322 nmol/L and CD4 lymphocyte counts of below 500/microL developed AIDS in 3 years. This represents an 18.4-fold increased relative hazard at 3 years over individuals with beta 2M and CD4 cell counts within the reference range for uninfected individuals. A nomogram is provided that allows the easy calculation of the probability of an HIV-infected person developing AIDS in 36 months depending on prevalent levels of CD4 lymphocytes and serum beta 2M.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967523

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

1.  Immunological markers of disease progression in patients infected with the human immunodeficiency virus.

Authors:  J M Pascale; M D Isaacs; P Contreras; B Gomez; L Lozano; E Austin; M C De Martin; R L Gregory; G L McLaughlin; A Amador
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Clinical and immunological assessment of HIV infection.

Authors:  A G Bird
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

3.  CD8 T lymphocyte subset markers and HIV infection.

Authors:  A G Bird; K C Watret
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

4.  BETA-2-MICROGLOBULIN LEVELS IN HUMAN-IMMUNODEFICIENCY VIRUS INFECTED SUBJECTS.

Authors:  Mkk Rao; S K Sayal; S S Uppal; R M Gupta; V C Ohri; S Banerjee
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 5.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

6.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 7.  Recent advances in the medical management of early HIV disease.

Authors:  P A Volberding
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

8.  Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection.

Authors:  Mariana Varela; Lisa Landskron; Rachel P J Lai; Trevelyan J McKinley; Willy M Bogers; Ernst J Verschoor; Rob Dubbes; Susan W Barnett; Simon D W Frost; Jonathan L Heeney
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

Review 9.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

10.  beta-2 Microglobulin values among human immunodeficiency virus (HIV)-negative, HIV-positive asymptomatic, and HIV-positive symptomatic Ugandans.

Authors:  E M Piwowar; S B Tugume; R M Grant; T Lutalo; K Pattishall; E Katongole-Mbidde
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.